Breast Cancer Research and Treatment最新文献

{"title":"Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study.","authors":"Endre Gabrielsen, Tom Wilsgaard, Hanne Frydenberg, Trygve Lofterød, Stig Manfred Dalen, Elin Mortensen, Marit D Solbu, Hawa Nalwoga, Lars A Akslen, Egil S Blix, Hege S Haugnes","doi":"10.1007/s10549-025-07786-4","DOIUrl":"10.1007/s10549-025-07786-4","url":null,"abstract":"<p><strong>Purpose: </strong>Syndecans are transmembrane proteins involved in inflammation and signaling pathways. Their potential role as pre-diagnostic biomarkers for breast cancer risk remains unexplored. This study aimed to investigate whether pre-diagnostic serum syndecan levels are associated with breast cancer risk in a population-based cohort.</p><p><strong>Methods: </strong>We conducted a case-cohort study nested within the Tromsø Study (Norway), including women who participated in the fifth survey (2001). Women with incident breast cancer (cases, n = 158) through 2022 were identified, with a random sub-cohort of 708 women. Serum levels of syndecan-1 (SDC1) and syndecan-4 (SDC4) were measured using ELISA on frozen serum samples obtained in 2001. All participants were stratified into quartiles (Q1-Q4) based on pre-diagnostic levels. Cox proportional hazards regression models assessed associations between serum syndecan levels and breast cancer risk.</p><p><strong>Results: </strong>The median age at diagnosis was 69 years for cases, and 83.3% of tumors were hormone receptor-positive (HR +). Women with higher serum SDC4 (Q2-Q4) levels had approximately a twofold increased risk of breast cancer compared to women in Q1. We observed a nearly threefold increased risk for the HR + subtype. In postmenopausal women, HRs for HR + breast cancer in Q2, Q3, and Q4 were 3.81 (95% CI: 1.57-9.23), 3.43 (95% CI: 1.41-8.40), and 3.54 (95% CI: 1.45-8.65), respectively, all relative to Q1 of SDC4. No associations were observed between SDC1 levels and breast cancer risk.</p><p><strong>Conclusions: </strong>Our results suggest that SDC4 may play a role in the initiation and early progression of breast cancer.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"365-375"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe.","authors":"Olga Oikonomidou, Mark J Beresford, Elena Galve-Calvo, Achim Woeckel, Rohan C Parikh, Abigail Hitchens, Connie Chen, Justin Doan, Benjamin Li, Valerie Derrien Ansquer, Gaelle Frugier, Maria I Jimenez, Keith L Davis, Edward I Broughton","doi":"10.1007/s10549-025-07707-5","DOIUrl":"10.1007/s10549-025-07707-5","url":null,"abstract":"<p><strong>Purpose: </strong>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy is the recommended first-line (1L) treatment for hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Real-world evidence (RWE) describing 1L CDK4/6i regimens and associated clinical outcomes in Europe is limited. The study objective was to describe clinical characteristics, tumor response, and survival outcomes in patients with HR+/HER2- ABC.</p><p><strong>Methods: </strong>This retrospective, observational cohort study used data from 52 treatment centers in the UK, Spain, and Germany and included patients who initiated 1L palbociclib + aromatase inhibitor (AI) therapy for ABC between 2016 and 2020. Primary endpoints were real-world progression-free survival (rwPFS) and overall survival (OS).</p><p><strong>Results: </strong>Data were abstracted from 856 patients. During treatment, complete response, partial response, or stable disease was achieved for 86.1% of patients in Spain, 80.7% in the UK, and 79.0% in Germany, while complete or partial response was achieved for 43.8% of patients in Spain, 34.9% in the UK, and 16.9% in Germany. Median rwPFS during treatment was 28.1 months for patients in Spain, 33.9 months in the UK, and 48.1 months in Germany. Median OS was 51.3 months (95% CI 46.6-NE) in the UK, 65.2 months (95% CI 65.2-NE) in Germany, and not reached in Spain.</p><p><strong>Conclusion: </strong>This RWE supports the clinical effectiveness of 1L palbociclib + AI in routine clinical practice in European countries-consistent with the efficacy observed in clinical trials-and further supports the implementation of palbociclib-based regimens as frontline treatment of HR+/HER2- ABC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"299-312"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.","authors":"Erica M Stringer-Reasor, Poornima Saha, Masha Kocherginsky, Ricardo Lastra, Gabrielle Baker, Ernst Lenygel, Theodore Karrison, Lauren Olalde, Elizabeth Mokrzycki, Olwen M Hahn, Philip C Hoffman, Suzanne D Conzen, Gini F Fleming, Rita Nanda","doi":"10.1007/s10549-025-07783-7","DOIUrl":"10.1007/s10549-025-07783-7","url":null,"abstract":"<p><strong>Purpose: </strong>Preclinical models of glucocorticoid receptor (GR)-positive breast cancer (BC) and ovarian cancer (OC) suggest GR activity inhibits chemotherapy-induced apoptosis, and GR antagonism using mifepristone (Mif) enhances cytotoxicity. We performed a phase I trial combining mifepristone, carboplatin (C), gemcitabine (G).</p><p><strong>Methods: </strong>A standard \"3 + 3\" dose escalation scheme was used. Objectives were safety and to determine the maximum tolerated dose (MTD) of Mif + CG. CG was administered intravenously on days 1 and 8 of a 21-day cycle, and mifepristone was administered orally the day before and day of chemotherapy.</p><p><strong>Results: </strong>Thirty-one patients enrolled with a median age of 54 years; the median prior metastatic regimens were one. Twenty-five patients were evaluable for dose-limiting toxicities (DLT) including 16 BC and 9 OC. Dose was de-escalated to dose level (DL) -1 due to 2/4 neutropenia-related DLT's. DLT definition was updated to exclude hematologic DLTs starting at DL-1. The dose  was further de-escalated due to neutropenia, and 2/3, 1/4 and 0/6 patients experienced a DLT at DL-1, DL-2, and DL-3, respectively. At DL-1, prophylactic pegylated granulocyte colony-stimulating factor (G-CSF) was instituted. Dose levels -1 and -2 were expanded to add 3 and 6 patients, respectively, to evaluate tolerability  in dose levels -1a and -2a. There were 3 major responses (1CR, 2PR) at DL1, and 1 CR at DL-1. No responses were observed at lower levels.</p><p><strong>Conclusion: </strong>The MTD was carboplatin AUC 2  + gemcitabine 600 mg/m² on D1 and 8 with Mif 300 mg D-1 and D1 with pegylated G-CSF administered on day 9 of a 21-day cycle.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"347-354"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.","authors":"Sunhyung Choi, Bombi Park, Eun-Gyeong Lee, Seeyoun Lee, Han-Sung Kang, So-Youn Jung, Dong-Eun Lee, Jai-Hong Han","doi":"10.1007/s10549-025-07768-6","DOIUrl":"10.1007/s10549-025-07768-6","url":null,"abstract":"<p><strong>Purpose: </strong>Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer with variable risk of upstaging to invasive carcinoma. Accurate preoperative risk stratification is critical to guide management decisions and minimize overtreatment. This study aimed to identify clinicopathological and imaging predictors of DCIS upstaging to invasive cancer.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 701 patients diagnosed with DCIS, among whom 200 (28.5%) were upstaged to microinvasive or invasive carcinoma. Logistic regression was used to evaluate the association between upstaging and various factors, including tumor size, nuclear grade, comedo necrosis, progesterone receptor (PR) negativity, human epidermal growth factor receptor 2 (HER2) overexpression, and mammographic findings.</p><p><strong>Results: </strong>Tumor size > 5 cm, comedo necrosis, PR negativity, and mammographic microcalcifications were independent predictors of upstaging. While HER2 overexpression was significant in univariate analysis, it was not retained in the multivariate model. Non-mass lesions on ultrasound and magnetic resonance imaging (MRI) were not significant predictors.</p><p><strong>Conclusion: </strong>Integrating these markers into preoperative risk stratification models may improve individualized treatment planning and reduce overtreatment in patients with DCIS.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"325-334"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence.","authors":"Anikó Kovács, Leif Klint, Barbro Linderholm, Toshima Z Parris","doi":"10.1007/s10549-025-07776-6","DOIUrl":"10.1007/s10549-025-07776-6","url":null,"abstract":"<p><strong>Background: </strong>HER2-targeted therapies have improved survival in HER2-positive breast cancer, and recent data suggest potential benefits for patients with HER2-low tumors (defined as immunohistochemistry (IHC) 1 + or 2 + and, in situ hybridization (ISH)-negative). HER2-low tumors are heterogenous, spanning the hormone receptor-positive and triple-negative subtypes. Assessing HER2-low and HER2-ultralow status remains challenging, especially across specimen types.</p><p><strong>Aims: </strong>This study aims to (1) compare HER2 assessment using conventional microscopy, digital pathology, and an artificial intelligence (AI) model, and (2) investigate changes in HER2-low status between core biopsies, surgical specimens, and metastases.</p><p><strong>Materials and methods: </strong>IHC slides from 47 HER2-low advanced breast carcinomas were analyzed using conventional microscopy, digital pathology, and an AI model developed on Aiforia® Create. HER2 statuses were categorized as low, ultralow (score 1 + in 1-10%), and null (score 0 or 1 + in < 1% with difficult-to-interpret minimal membranous-like staining). Changes in HER2 expression across specimen types were evaluated using agreement measures and visualization tools.</p><p><strong>Results: </strong>The AI model identified more HER2-low and HER2-ultralow cases compared to conventional methods, improving detection accuracy. HER2 expression differed between specimen types, with metastases exhibiting increased HER2 expression compared to surgical specimens and core biopsies. Digital pathology also showed stronger membranous staining and identified more HER2 expressor tumor cells with any kind of membranous staining than microscopy.</p><p><strong>Conclusions: </strong>AI evaluation is a more sensitive method for HER2-low assessment and reveals expression changes across disease progression. These findings emphasize the need for standardized HER2 assessment to ensure accurate therapy eligibility, particularly for novel treatments like Trastuzumab-Deruxtecan.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"397-408"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis.","authors":"Małgorzata Pieniążek, Anna Polakiewicz-Gilowska, Manuela Las-Jankowska, Jakub Wronowicz, Michał Jarząb, Aleksandra Łacko, Mirosława Püsküllüoğlu","doi":"10.1007/s10549-025-07825-0","DOIUrl":"https://doi.org/10.1007/s10549-025-07825-0","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the prognostic significance of baseline laboratory parameters and inflammatory indices in patients with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in the second line and beyond, potentially aiding personalized patient management.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed data from 83 female patients with mTNBC who initiated SG therapy at four Polish oncology centers between August 2021 and September 2024. Hematological parameters-white blood cell count (WBC), hemoglobin (Hb), platelets (Plt) and inflammatory indices-neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were assessed at baseline and before each dose of first four SG cycles. Median progression-free survival (mPFS) and overall survival (mOS) were estimated, and, as the primary objectives, associations between baseline laboratory variables and survival outcomes were assessed using multivariate Cox regression models (α = 0.05). Secondary objectives included assessing their associations with patient and disease characteristics, prior treatment lines, and adverse events (AEs), which were classified using the National Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE), version 5.0.</p><p><strong>Results: </strong>The mPFS was 4.07 months (95% CI 3.05-6.18), while the mOS was 8.01 months (95% CI 6.05-9.75). Lower baseline Hb was significantly associated with shorter PFS (HR = 0.82, p = 0.03) but not OS. Elevated baseline NLR predicted worse OS (HR = 1.18, p = 0.03), while PLR and SII lacked prognostic significance. Changes in blood parameters within initial four SG cycles showed no significant correlations with survival outcomes. Furthermore, baseline hematological markers and inflammatory indices showed no significant association with clinical characteristics, prior therapy lines, tumor burden, or the occurrence and severity of AEs.</p><p><strong>Conclusions: </strong>Baseline Hb and NLR were identified as independent prognostic biomarkers in patients with mTNBC receiving SG treatment, predicting PFS and OS, respectively. Other inflammatory indices (PLR, SII) did not demonstrate prognostic relevance. Prospective validation in larger cohorts is essential to confirm these findings and potentially guide personalized treatment strategies.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145173379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term follow-up confirms patients with high-risk breast lesions can be successfully managed at a multidisciplinary conferences.","authors":"Wei Yang, Ashlyn Alongi, Zhongliang Ma, Toncred M Styblo, Cletus A Arciero, Clara Farley, Christopher Ho, Ruth M O'Regan, Michael A Cohen, Neeti Bagadiya, Xiaoxian Li","doi":"10.1007/s10549-025-07826-z","DOIUrl":"https://doi.org/10.1007/s10549-025-07826-z","url":null,"abstract":"<p><strong>Background: </strong>The management of high-risk breast lesions is controversial. There is a lack of long-term follow-up studies to evaluate clinical management decisions.</p><p><strong>Methods: </strong>We included 267 consecutive high-risk breast lesions with pathology-radiology concordance that were prospectively recommended for surgery or follow-up at a multidisciplinary conference. The 267 lesions included 149 papillomas and 118 other high-risk lesions. The 149 papillomas included 119 benign papillomas, 17 atypical papillomas, 6 papillomas with adjacent atypical ductal hyperplasia (ADH), 7 papillomas with adjacent atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS). The 118 high-risk lesions included 43 ADH, 36 radial scar (RS), 23 ALH, 13 LCIS, 2 flat epithelial atypia (FEA), and 1 mucocele-like lesion (ML). The patients were recommended for surgery or follow-up using established guidelines.</p><p><strong>Results: </strong>90 (60.4%) patients with papillomas, who did not undergo immediate excision and were followed, had a median follow-up time of 61.6 months; 70 patients had a follow-up time > 2 years (25.1-103.4 months). Two patients (2.1%) with benign papilloma had history of breast cancer and developed carcinoma in 62.7 at the lumpectomy site and 40.8 months at the biopsy site which showed 2 mm benign papilloma; both papillomas were sufficiently sampled, and we believe the recommendation of follow-up to both patients was appropriate. 65 (55.1%) patients with other high-risk lesions, who did not undergo excision and were followed, had a median follow-up time of 64.1 months; 50 patients had a follow-up time > 2 years (24.2-101.6 months). Four (6.2%) of these 65 patients developed carcinoma during follow-up including 2 patients with ADH who were recommended for surgery but chose for follow-up; 1 patient with ALH developed invasive carcinoma in a different quadrant at 76.6 months; and 1 patient with RS developed invasive carcinoma in the same quadrant at 51.2 months. In the 112 patients who underwent immediate excision, all upgrades (n = 15) occurred in patients who were recommended for surgery. During follow-up of these 112 patients, 2 patients developed carcinoma and both had benign pathology in the excisional specimens.</p><p><strong>Conclusions: </strong>This long-term follow-up study confirms that a multidisciplinary conference can successfully triage patients with high-risk breast lesions to surgery or follow-up with established guidelines and careful pathology, radiology, and clinical evaluations. Patients with high-risk breast lesions have increased cancer risk and should be followed.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence.","authors":"Anikó Kovács, Leif Klint, Barbro Linderholm, Toshima Z Parris","doi":"10.1007/s10549-025-07828-x","DOIUrl":"https://doi.org/10.1007/s10549-025-07828-x","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145147858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2- breast cancer patients after neoadjuvant chemotherapy.","authors":"Zhenhua Huang, Yao Liu, Shunying Li, Yudong Li, Zongqi Wu, Haiyan He, Yaping Yang, Liang Jin","doi":"10.1007/s10549-025-07824-1","DOIUrl":"https://doi.org/10.1007/s10549-025-07824-1","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Analysis of the impact of the COVID-19 pandemic on the stage at diagnosis in breast cancer patients at a French comprehensive cancer centre, through two different methods: a preliminary study.","authors":"Alessandra Zago, Emilie Lévêque, Aline Augustynen, Marianne Leheurteur, Marie Ottaviani, Agnès Loeb, Thomas Vermeulin","doi":"10.1007/s10549-025-07813-4","DOIUrl":"https://doi.org/10.1007/s10549-025-07813-4","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}